A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of
Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426)
The purpose of this study is to compare the safety and effects of the combination of pembrolizumab, a research study drug, and axitinib with sunitinib alone on participants and their metastatic renal cell carcinoma.
Metastatic renal cell carcinoma
18 years or older with diagnosed metastatic renal cell carcinoma. Further exams, tests, and procedures will be done to confirm eligibility.
18 - 120
Healthy Volunteers Needed
Duration of Participation
For as long as the participant is seeing benefit
Knight Clinical Trials
Merck Sharp & Dohme Corp